Related Experiment Video
Updated: Jun 2, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation
1Heritage Medical Research Centre, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB Canada.
Abstract:
Although MDM2 is known to be a critical negative regulator of p53, MDM2 only catalyzes p53 mono- or multiple monoubiquitination in vitro and in vivo, which is insufficient for the initiation of proteasomal degradation. MDM2 does not polyubiquitinate p53 in vitro, however, which indicates that the activity of other ubiquitin ligase(s) or cofactor(s) is required for MDM2-mediated p53 polyubiquitination and degradation. In our recent study, we demonstrated that UBE4B, an E3 and E4 ubiquitin ligase with a U-box domain, interacts physically with both p53 and MDM2. Our findings revealed that UBE4B negatively regulates the level of p53 and inhibits p53-dependent transactivation and apoptosis. We propose that inhibition of MDM2 binding to UBE4B may provide another approach to inhibit MDM2 E3 ligase activity for tumor suppressor p53. It could lead to novel anticancer therapies, with the possibility of reducing the public health burden from cancer.
Insights
UBE4B, a ubiquitin ligase, interacts with MDM2 and p53, leading to p53 degradation. Inhibiting this interaction may offer new anticancer therapies by restoring tumor suppressor p53 function.
Area of Science:
- Molecular Biology
- Cancer Research
- Ubiquitination Pathways
Background:
- MDM2 is a key negative regulator of the tumor suppressor p53.
- MDM2 alone performs insufficient ubiquitination for p53 proteasomal degradation, implying cofactor involvement.
- The precise mechanisms of MDM2-mediated p53 degradation require further elucidation.
Purpose of the Study:
- To investigate the role of UBE4B in p53 regulation and degradation.
- To determine the interaction between UBE4B, MDM2, and p53.
- To explore novel therapeutic strategies targeting the MDM2-UBE4B interaction.
Main Methods:
- Co-immunoprecipitation assays to confirm physical interactions between UBE4B, MDM2, and p53.
- Western blotting to assess p53 protein levels.
- Analysis of p53-dependent transactivation and apoptosis assays.
Main Results:
- UBE4B physically interacts with both p53 and MDM2.
- UBE4B negatively regulates p53 protein levels.
- UBE4B inhibits p53-dependent transactivation and apoptosis.
Conclusions:
- UBE4B acts as a crucial E3/E4 ubiquitin ligase in the p53 degradation pathway, working in conjunction with MDM2.
- Targeting the MDM2-UBE4B interaction presents a potential therapeutic strategy to reactivate p53 for cancer treatment.
- This approach could contribute to reducing the global cancer burden.
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Anaphase Promoting Complex
Anaphase Promoting Complex
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...

